Liminatus Pharma Inc
liminatuspharma.comWhat Do They Do?
Develops a humanized antibody therapy that blocks a cancer-related immune checkpoint for patients with advanced solid cancers, including lung cancer.
10-K for FY2025, filed Mar 31, 2026
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 31, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$1.4MView ↗
- ▼ Now a loss
- vs $113.3K in Q2 FY2025
-
Aug 18, 2026
Nasdaq approved transfer to its Capital Market
The company received an exception to regain compliance with listing rules, including the minimum bid-price requirement.
Sources
8-K, filed Aug 18, 2026
On July 31, 2026, the Panel notified the Company that it had determined to transfer the Company to The Nasdaq Capital Market effective…View ↗
-
Jul 6, 2026
Liminatus completed its acquisition of InnocsAI
Liminatus completed the merger and acquired InnocsAI.
Sources
8-K, filed Jul 6, 2026
On July 2, 2026, the Company, InnocsAI, and Merger Sub consummated the Merger described in Item 1.01 above, pursuant to which the Company…View ↗
Who Do They Compete With?
Competes with Amgen, AstraZeneca, BMS, Merck, Novartis, Pfizer, Roche, Genentech, Forty Seven, and Gilead Sciences
10-K for FY2025, filed Mar 31, 2026We face competition with respect to our current product candidate and will face competition with respect to future product candidates from…View ↗
Loading...
